In this talk, we dive into the critical quality attributes (CQAs) of mRNA and lipid nanoparticles (LNPs) that directly impact drug efficacy and safety. You’ll gain insights into essential and cutting-edge analytical techniques and nanopore sequencing, mass spectrometry, and laser-induced…
Pioneering mRNA Therapies to Combat Hypercholesterolemia and Improve Long-Term Health Repair Biotechnologies, a preclinical biotech, is developing innovative therapies for age-related diseases such as hypercholesterolemia. Their lead asset aims to address the underlying cause of atherosclerosis, representing their ambition to…
New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver Innovative Therapies Faster. COLCHESTER, Vt., October 31, 2024 /BUSINESS WIRE/ — Vernal Biosciences Inc., a leader in mRNA and lipid nanoparticle (LNP) development, manufacturing, and…
Nature Nanotechnology: Tissue-Specific mRNA Therapeutic Delivery Researchers have developed a combinatorial design of siloxane-incorporated LNPs to enhance tissue-specific mRNA therapeutic delivery. This article explains how this approach improves intracellular processing and stability of mRNA, showing promise for targeted treatments and…
In this video series exploring biotech innovation, Christian Cobaugh, founder and CEO of Vernal, discusses the critical role of analytical services in the success of mRNA and lipid nanoparticles (LNPs) therapeutics. Interviewed by Kristyn Cook, Executive Director of Marketing, he…
COLCHESTER, Vt., October 9, 2024 — Vernal Biosciences, a leader in mRNA and lipid nanoparticle (LNP) manufacturing, announces that its analytical and quality control (QC) services for plasmid DNA, mRNA, and LNPs are now commercially available as part of its…
In the fast-paced world of early-stage mRNA product and process development, it’s not just about ideas and innovation; it’s about how quickly and accurately you can measure your outcomes. Since those precious outcomes depend on the confidence you have in…
Speaking of Mol Bio Podcast In the latest episode (Season 2, Episode 8) of the Speaking of Mol Bio Podcast, hosts Steve Lewis and Dr. Christian Cobaugh, CEO of Vernal Biosciences, delve into the fascinating world of mRNA technology. The…
In the latest episode of the Speaking of Mol Bio Podcast, hosts Steve Lewis and Dr. Christian Cobaugh, CEO of Vernal Biosciences, delve into the fascinating world of mRNA technology. The COVID pandemic has brought mRNA into the spotlight, showcasing…
Podcast Abstract: In the latest episode of the Absolute Gene-ius Podcast, hosts Christina Bouwens and Dr. Christian Cobaugh, CEO of Vernal Biosciences, dive into the evolving landscape of mRNA technology and democratizing mRNA technology. With a mission to enhance access…
Rapid Single Epitope mRNA Production This article presents a synthetic DNA template (SDT) process for manufacturing single epitope mRNA, offering a flexible, cost-efficient, and rapid alternative to traditional plasmid DNA templates (PDT). Read the article to explore what can be…
Authored by: Christian Cobaugh, Grant Henderson and Khaled Yamout The FDA’s new guidance clarifies eligible Platform Technologies must adhere to the statutory definition and require consistent CMC processes. Applicants can recycle features across products, while those lacking assets can leverage CDMOs like…